← board
BKHA
distress 0/10 · well-funded / low risk$13.10+8%today0% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
0%
Price & events
+13.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+8.2%
1D
+9.5%
1W
+10.0%
1M
+12.7%
3M
+13.9%
6M
+19.1%
1Y
+29.2%
2Y
—
5Y
+29.3%
All
Overview
- Market Cap
- $54.41M
- Volume
- 700
- 52 Week Range
- $10.65 – $13.10
- Total Shares
- 4.15M
- Float Shares
- 1.24M
- Short %
- 0.00%
- % Held by Insiders
- 53.00%
- % Held by Institutions
- 51.44%
- RVOL
- 0.66x
- Beta
- 0.03
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 4,153,577 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.